Influence of metabolic state and body composition on the action
of pharmacological treatment of migraine

J 2024

Influence of metabolic state and body composition on the action of pharmacological treatment of migraine

BRUIJN, Noor, van Lohuizen ROMY, Malgorzata BORON, Mira FITZEK, Francesca GABRIELE et. al.

Základní údaje

Originální název

Influence of metabolic state and body composition on the action of pharmacological treatment of migraine

Autoři

BRUIJN, Noor, van Lohuizen ROMY, Malgorzata BORON, Mira FITZEK, Francesca GABRIELE, Giada GIULIANI, Laura MELGAREJO, Pavel ŘEHULKA (203 Česká republika, domácí), Gabriele SEBASTIANELLI, Paul TRILLER, Simone VIGNERI, Behiye OZCAN a van den Brink Antoinette MAASSEN

Vydání

JOURNAL OF HEADACHE AND PAIN, LONDON, BMC, 2024, 1129-2369

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.400 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1186/s10194-024-01724-3

UT WoS

001160025300001

Klíčová slova anglicky

CGRP; Metabolic disorders; Diabetes mellitus; Migraine; Obesity; Lifestyle

Štítky

14110127, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 4. 2024 14:09, Mgr. Tereza Miškechová

Anotace

V originále

Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendously and, in addition, it is associated with highly prevalent metabolic diseases, such as obesity, diabetes mellitus and thyroid dysfunction. Also, the clinical response to drugs might be affected in patients with metabolic disease due to body composition and metabolic change. Therefore, the efficacy of antimigraine drugs could be altered in patients with both migraine and metabolic disease. However, knowledge of the pharmacology and the related clinical effects of antimigraine drugs in patients with metabolic disease are limited. Therefore, and given the clinical relevance, this article provides a comprehensive overview of the current research and hypotheses related to the influence of metabolic state and body composition on the action of antimigraine drugs. In addition, the influence of antimigraine drugs on metabolic functioning and, vice versa, the influence of metabolic diseases and its hormonal modulating medication on migraine activity is outlined. Future exploration on personalizing migraine treatment to individual characteristics is necessary to enhance therapeutic strategies, especially given its increasing significance in recent decades.

Návaznosti

LM2023049, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network

Citovat

BRUIJN, Noor, van Lohuizen ROMY, Malgorzata BORON, Mira FITZEK, Francesca GABRIELE, Giada GIULIANI, Laura MELGAREJO, Pavel ŘEHULKA, Gabriele SEBASTIANELLI, Paul TRILLER, Simone VIGNERI, Behiye OZCAN a van den Brink Antoinette MAASSEN. Influence of metabolic state and body composition on the action of pharmacological treatment of migraine. JOURNAL OF HEADACHE AND PAIN. LONDON: BMC, 2024, roč. 25, č. 1, s. 1-22. ISSN 1129-2369. Dostupné z: https://dx.doi.org/10.1186/s10194-024-01724-3.

@article{2398063,
   author = {Bruijn, Noor and Romy, van Lohuizen and Boron, Malgorzata and Fitzek, Mira and Gabriele, Francesca and Giuliani, Giada and Melgarejo, Laura and Řehulka, Pavel and Sebastianelli, Gabriele and Triller, Paul and Vigneri, Simone and Ozcan, Behiye and Maassen, van den Brink Antoinette},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s10194-024-01724-3},
   keywords = {CGRP; Metabolic disorders; Diabetes mellitus; Migraine; Obesity; Lifestyle},
   language = {eng},
   issn = {1129-2369},
   journal = {JOURNAL OF HEADACHE AND PAIN},
   title = {Influence of metabolic state and body composition on the action of pharmacological treatment of migraine},
   url = {https://www.mdpi.com/2227-9059/12/2/404},
   volume = {25},
   year = {2024}
}

TY  - JOUR
ID  - 2398063
AU  - Bruijn, Noor - Romy, van Lohuizen - Boron, Malgorzata - Fitzek, Mira - Gabriele, Francesca - Giuliani, Giada - Melgarejo, Laura - Řehulka, Pavel - Sebastianelli, Gabriele - Triller, Paul - Vigneri, Simone - Ozcan, Behiye - Maassen, van den Brink Antoinette
PY  - 2024
TI  - Influence of metabolic state and body composition on the action of pharmacological treatment of migraine
JF  - JOURNAL OF HEADACHE AND PAIN
VL  - 25
IS  - 1
SP  - 1-22
EP  - 1-22
PB  - BMC
SN  - 11292369
KW  - CGRP
KW  - Metabolic disorders
KW  - Diabetes mellitus
KW  - Migraine
KW  - Obesity
KW  - Lifestyle
UR  - https://www.mdpi.com/2227-9059/12/2/404
N2  - Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendously and, in addition, it is associated with highly prevalent metabolic diseases, such as obesity, diabetes mellitus and thyroid dysfunction. Also, the clinical response to drugs might be affected in patients with metabolic disease due to body composition and metabolic change. Therefore, the efficacy of antimigraine drugs could be altered in patients with both migraine and metabolic disease. However, knowledge of the pharmacology and the related clinical effects of antimigraine drugs in patients with metabolic disease are limited. Therefore, and given the clinical relevance, this article provides a comprehensive overview of the current research and hypotheses related to the influence of metabolic state and body composition on the action of antimigraine drugs. In addition, the influence of antimigraine drugs on metabolic functioning and, vice versa, the influence of metabolic diseases and its hormonal modulating medication on migraine activity is outlined. Future exploration on personalizing migraine treatment to individual characteristics is necessary to enhance therapeutic strategies, especially given its increasing significance in recent decades.
ER  -

BRUIJN, Noor, van Lohuizen ROMY, Malgorzata BORON, Mira FITZEK, Francesca GABRIELE, Giada GIULIANI, Laura MELGAREJO, Pavel ŘEHULKA, Gabriele SEBASTIANELLI, Paul TRILLER, Simone VIGNERI, Behiye OZCAN a van den Brink Antoinette MAASSEN. Influence of metabolic state and body composition on the action of pharmacological treatment of migraine. \textit{JOURNAL OF HEADACHE AND PAIN}. LONDON: BMC, 2024, roč.~25, č.~1, s.~1-22. ISSN~1129-2369. Dostupné z: https://dx.doi.org/10.1186/s10194-024-01724-3.

Podrobný výpis o publikaci